OBJECTIVE: Our objective was to determine the association between viral load of high risk human papilloma virus (HPV) using the Hybrid Capture II (HC II) system and cervical intraepithelial neoplasia (CIN) lesion stage. METHODS: A total of 182 consecutive women with confirmed diagnoses of CIN 1-3 and 182 healthy women with negative Pap were included. All subjects underwent structured interviews focused on socioeconomic and reproductive factors. HC II testing was used to detect human papilloma virus (HPV) DNA. Viral load was measured by light measurements expressed as relative lights unit (RLU) ratio (specimens/control). Log(10)RLU ratios were categorized for analysis into four groups: negative (</=0); low viral load (0.01-1.0), middle viral load (1.01-2.0), and high viral load (2.0-3.6). Frequencies and association measurement odds ratio (OR) adjusted by unconditional multinomial regression (UMR) were used in analysis. RESULTS: A total of 75 of 80 (93.7%) patients with CIN 2-3, 82 of 101 (79.4%) with CIN 1, and 36 of 182 (19.8%) controls were positive for HPV DNA. The higher the viral load of HPV DNA infection observed, the higher the probability of being associated with stage of CIN (P <0.001). Association between low viral load HPV and CIN 1 was 16.8 (7.2-39) compared with the highest association observed with high viral load and CIN 2-3 (OR(a) = 365.8, 94.7-1412). Both control and cases in the oldest women presented the highest viral load. CONCLUSIONS: We found high frequencies of HPV DNA in CIN 1 and in CIN 2-3 patients. A clear association between viral load of HPV DNA was determined by HC II assay and CIN stage.
OBJECTIVE: Our objective was to determine the association between viral load of high risk human papilloma virus (HPV) using the Hybrid Capture II (HC II) system and cervical intraepithelial neoplasia (CIN) lesion stage. METHODS: A total of 182 consecutive women with confirmed diagnoses of CIN 1-3 and 182 healthy women with negative Pap were included. All subjects underwent structured interviews focused on socioeconomic and reproductive factors. HC II testing was used to detect human papilloma virus (HPV) DNA. Viral load was measured by light measurements expressed as relative lights unit (RLU) ratio (specimens/control). Log(10)RLU ratios were categorized for analysis into four groups: negative (</=0); low viral load (0.01-1.0), middle viral load (1.01-2.0), and high viral load (2.0-3.6). Frequencies and association measurement odds ratio (OR) adjusted by unconditional multinomial regression (UMR) were used in analysis. RESULTS: A total of 75 of 80 (93.7%) patients with CIN 2-3, 82 of 101 (79.4%) with CIN 1, and 36 of 182 (19.8%) controls were positive for HPV DNA. The higher the viral load of HPV DNA infection observed, the higher the probability of being associated with stage of CIN (P <0.001). Association between low viral load HPV and CIN 1 was 16.8 (7.2-39) compared with the highest association observed with high viral load and CIN 2-3 (OR(a) = 365.8, 94.7-1412). Both control and cases in the oldest women presented the highest viral load. CONCLUSIONS: We found high frequencies of HPV DNA in CIN 1 and in CIN 2-3 patients. A clear association between viral load of HPV DNA was determined by HC II assay and CIN stage.
Authors: M Marks; P E Gravitt; U Utaipat; S B Gupta; K Liaw; E Kim; A Tadesse; C Phongnarisorn; V Wootipoom; P Yuenyao; C Vipupinyo; S Rugpao; S Sriplienchan; D D Celentano Journal: J Clin Virol Date: 2011-03-09 Impact factor: 3.168
Authors: Rachel L Winer; Tiffany G Harris; Long Fu Xi; Kathrin U Jansen; James P Hughes; Qinghua Feng; Carolee Welebob; Jesse Ho; Shu-Kuang Lee; Joseph J Carter; Denise A Galloway; Nancy B Kiviat; Laura A Koutsky Journal: J Med Virol Date: 2009-04 Impact factor: 2.327
Authors: S-M A Kulmala; S M Syrjänen; U B Gyllensten; I P Shabalova; N Petrovichev; P Tosi; K J Syrjänen; B C Johansson Journal: J Clin Pathol Date: 2006-02-16 Impact factor: 3.411
Authors: L Del Río-Ospina; S C Soto-DE León; M Camargo; R Sánchez; D A Moreno-Pérez; A Pérez-Prados; M E Patarroyo; M A Patarroyo Journal: Epidemiol Infect Date: 2017-02-10 Impact factor: 4.434
Authors: Luisa Del Río-Ospina; Sara Cecilia Soto-De León; Milena Camargo; Darwin Andrés Moreno-Pérez; Ricardo Sánchez; Antonio Pérez-Prados; Manuel Elkin Patarroyo; Manuel Alfonso Patarroyo Journal: BMC Cancer Date: 2015-03-05 Impact factor: 4.430
Authors: Milagros Bernal; Isabel Burillo; Jose I Mayordomo; Manuel Moros; Rafael Benito; Joaquina Gil Journal: Infect Agent Cancer Date: 2008-05-29 Impact factor: 2.965